To help answer the question of the ideal timing of post prostate biopsy MRI, Dr. Vidit Sharma, from Mayo Clinic in Rochester, MN and his colleagues performed a study which they presented at the American Urologic Association’s 2019 annual meeting in Chicago, IL. Sharma and his group retrospectively identified nearly 400 men who underwent a mpMRI following a biopsy at his institution from 2002-2013. They then evaluated for post-biopsy hematoma using predominately T1 sequence images. They next used this data in a univariate and multivariate logistic regression analysis to determine the ideal time between biopsy and mpMRI to be able to most accurately identify hematoma. They determined that waiting at least 51 days decreased the likelihood of hematoma on mpMRI to only 19.5%, whereas men who underwent biopsy prior to 51 days had a 37% chance of hematoma. They determined that waiting at least 51 days decreased the likelihood of hematoma on mpMRI to only 19.5%, whereas men who underwent biopsy prior to 51 days had a 37% chance of hematoma (Figure 1).
Figure 1: Probability of post-biopsy hematoma as a measure of time
The group concludes that the time from prostate biopsy to mpMRI was an independent variable that could discriminate the probability of a visible post-biopsy hematoma. Their study helps provide an objective measure of the rates of hematoma formation on post-biopsy MRI that can help guide urologists with determining when to biopsy and can be useful for patient counseling.
Presented by: Vidit Sharma, MD, Mayo Clinic, Rochester, Minnesota
Written by: Brian Kadow, MD, Society of Urologic Oncology Fellow, Fox Chase Cancer Center @btkmduro at the American Urological Association's 2019 Annual Meeting (AUA 2019), May 3 – 6, 2019 in Chicago, Illinois